Overview
Breast cancer care in the UK has often relied on clinical trial data, which may not fully capture real-world patient experiences. To bridge this gap, Flatiron Health has developed a detailed electronic health record (EHR)-derived dataset. This study focuses on evaluating this dataset, which includes patients diagnosed with early-stage (eBC) or metastatic breast cancer (mBC) from 2016 to 2024.
By analyzing 1,451 patients, the study provides insights into patient demographics, clinical characteristics, and treatment patterns. The data reveals that most patients had early-stage breast cancer, with subtype distributions reflecting national benchmarks. Real-world overall survival rates were promising, with early-stage patients showing a 96.3% survival rate at one year.
Why this matters
This research marks a significant advancement in understanding breast cancer management in the UK. By utilizing EHR-derived data, the study offers a comprehensive view that aligns with national trends, confirming the dataset's clinical relevance. As the dataset expands to more NHS Trusts, it will support informed decision-making and policy development in breast cancer care. This approach not only enhances the ability to tailor treatment strategies but also aims to improve patient outcomes and healthcare delivery across the UK.